E
MTCR

Ergoteles’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Ergoteles’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,432
Closed -$8K – 2123
2022
Q1 		$8K Buy
+12,432
New +$6.52K ﹤0.01% 1163
2021
Q3 		– Sell
-29,900
Closed -$114K – 1819
2021
Q2 		$114K Buy
+29,900
New +$124K ﹤0.01% 1379

Other funds holding MTCR

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ergoteles's MTCR Position: Q2 2022 in Review

Ergoteles sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2022, closing a stake of 12,432 shares — an estimated $8K sold.

Ergoteles first reported a position in MTCR in Q2 2021 and held it in 2 quarters. The position peaked at $114K in Q2 2021. 25 funds tracked by Wall St. Rank hold MTCR as of Q2 2022.

  • Ergoteles reported no remaining Metacrine, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ergoteles sold 12,432 Metacrine, Inc. Common Stock shares in Q2 2022, an estimated $8K.
  • Ergoteles first reported a position in Metacrine, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Ergoteles's Metacrine, Inc. Common Stock position peaked at $114K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.